Premium
FDA reviewing ingestible sensor device to monitor Abilify compliance
Publication year - 2015
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30091
Subject(s) - food and drug administration , aripiprazole , business , computer science , medicine , internet privacy , pharmacology , psychiatry , schizophrenia (object oriented programming)
Although the Food and Drug Administration (FDA) is not allowed to discuss pending reviews, it has accepted the New Drug Application (NDA) for the combination product of Abilify, a brand of aripiprazole, embedded with a Proteus ingestible sensor. The FDA considered the NDA filed as of September 8. The below information comes from Otsuke Pharmaceuticals and Proteus.